From what I hear, one of the big issues slowing down the deal is the cost of clinical trials which the licensee would/may typically pay for. This could go into the hundreds of millions of dollars and therefore you could imagine the trade-offs being discussed in terms of upfront and royalty%.
Despite all of this, if the Biota negotiators are really good, they should be able to come up with a creative arrangement that works for both parties.
I would be happy for a lower upfront if I knew that a minimum annual units milestone was being met (with penalties if not met). The key would be that these milestones should also be up for regular reviews.
This is where I believe a Malcolm Turnbull style CEO with great business acumen/dealmaking skills would be an invaluable asset and would look at the organisation from a different perspective i.e. profits. If not this, as a shareholder, I would be happy for the organisation to spend $ on a high powered consultant to get a deal over the line on an agreed retainer plus a bonus dependant upon the deal.
- Forums
- ASX - By Stock
- biota what happened to you
From what I hear, one of the big issues slowing down the deal is...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online